Tacalyx
Tacalyx was founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany. The company aims to develop novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs). It is committed to glycan excellence against cancer, leveraging innovative research and first-in-class assets to target various solid human cancers with multiple treatment modalities.
Industries
Nr. of Employees
small (1-50)
Tacalyx
Products
Antibody-drug conjugate targeting tumor-associated carbohydrate antigen (early-stage asset)
An early-stage antibody-drug conjugate designed to deliver cytotoxic payloads to tumor cells via a tumor-associated carbohydrate antigen.
Early-stage pipeline of anti-TACA therapeutic assets
Pipeline of first-in-class assets targeting multiple tumor-associated carbohydrate antigens across solid tumor indications, designed for various modalities including ADCs and T-cell engagers.
Antibody-drug conjugate targeting tumor-associated carbohydrate antigen (early-stage asset)
An early-stage antibody-drug conjugate designed to deliver cytotoxic payloads to tumor cells via a tumor-associated carbohydrate antigen.
Early-stage pipeline of anti-TACA therapeutic assets
Pipeline of first-in-class assets targeting multiple tumor-associated carbohydrate antigens across solid tumor indications, designed for various modalities including ADCs and T-cell engagers.
Services
Collaborative research partnerships to discover and advance early-stage therapeutics against glycan targets, including target validation, antibody/nanobody generation and preclinical development.
Collaborative research partnerships to discover and advance early-stage therapeutics against glycan targets, including target validation, antibody/nanobody generation and preclinical development.
Expertise Areas
- Glyco-immunotherapy targeting Tumor-Associated Carbohydrate Antigens (TACAs)
- Antibody and nanobody discovery and engineering
- Antibody-drug conjugate (ADC) development
- T-cell engager modalities
Key Technologies
- Glycan-targeted therapeutic approaches
- Antibody engineering
- Nanobody technology
- Antibody-drug conjugates